|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
CA2547569C
(en)
*
|
2003-12-03 |
2013-04-16 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
|
EP1765853B1
(en)
|
2004-01-08 |
2015-10-28 |
ratiopharm GmbH |
O-linked glycosylation of G-CSF peptides
|
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
JP2008537680A
(ja)
*
|
2005-04-14 |
2008-09-25 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
|
|
EP1891231A4
(en)
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
CN101379077A
(zh)
|
2005-12-07 |
2009-03-04 |
夏洛特·豪泽 |
因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
|
|
EP2520586A1
(en)
*
|
2006-06-30 |
2012-11-07 |
The Regents of the University of Michigan |
Method of producing factor VIII proteins by recombinant methods
|
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー／エス |
ポリペプチドコンジュゲートの精製方法
|
|
CA2679107C
(en)
|
2007-02-23 |
2018-01-16 |
Sk Chemicals Co., Ltd. |
Process for producing and purifying factor viii and its derivatives
|
|
WO2008124406A2
(en)
|
2007-04-03 |
2008-10-16 |
Neose Technologies, Inc. |
Methods of treatment using glycopegylated g-csf
|
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
|
CN101965409A
(zh)
*
|
2007-11-01 |
2011-02-02 |
罗切斯特大学 |
具有增加的稳定性的重组因子viii
|
|
EP2242505A4
(en)
*
|
2008-01-08 |
2012-03-07 |
Biogenerix Ag |
GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
|
|
EP2626080A3
(en)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjugated factor VIII molecules
|
|
KR20110022604A
(ko)
*
|
2008-05-16 |
2011-03-07 |
바이엘 헬스케어 엘엘씨 |
표적화 응고 인자 및 그의 사용 방법
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
|
EP2482841B2
(en)
|
2009-10-02 |
2022-09-28 |
The Children's Hospital Of Philadelphia |
Compositions and methods for enhancing coagulation factor viii function
|
|
NZ703153A
(en)
|
2009-12-06 |
2015-02-27 |
Biogen Idec Hemophilia Inc |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
|
EP2591099B1
(en)
|
2010-07-09 |
2020-11-18 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
|
SG190136A1
(en)
*
|
2010-11-05 |
2013-07-31 |
Baxter Int |
A new variant of antihemophilic factor viii having increased specific activity
|
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
|
ES2722209T3
(es)
|
2011-07-08 |
2019-08-08 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos
|
|
US10656167B2
(en)
|
2011-07-25 |
2020-05-19 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
|
CN103917554B
(zh)
|
2011-10-18 |
2017-03-08 |
杰特有限公司 |
用于改善重构后纯化的因子viii的稳定性的方法
|
|
AU2012318303B2
(en)
|
2011-10-18 |
2015-09-03 |
Csl Behring Gmbh |
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
|
|
US9393289B2
(en)
|
2011-10-18 |
2016-07-19 |
Csl Behring Gmbh |
Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
|
|
HRP20181714T1
(hr)
|
2012-01-12 |
2018-12-28 |
Bioverativ Therapeutics Inc. |
Smanjenje imunogenosti protiv faktora viii kod pojedinaca koji su podvrgnuti terapiji faktora viii
|
|
NZ626945A
(en)
|
2012-01-12 |
2016-10-28 |
Biogen Ma Inc |
Chimeric factor viii polypeptides and uses thereof
|
|
DK3564260T5
(da)
*
|
2012-02-15 |
2024-09-02 |
Bioverativ Therapeutics Inc |
Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
キメラ性凝固因子
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
|
US10138291B2
(en)
|
2012-07-11 |
2018-11-27 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
WO2014018777A2
(en)
|
2012-07-25 |
2014-01-30 |
Biogen Idec Ma Inc. |
Blood factor monitoring assay and uses thereof
|
|
CA2888806A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
|
LT2956477T
(lt)
*
|
2013-02-15 |
2021-02-10 |
Bioverativ Therapeutics Inc. |
Optimizuotas faktoriaus viii genas
|
|
HUE047933T2
(hu)
|
2013-03-15 |
2020-05-28 |
Bioverativ Therapeutics Inc |
Faktor VIII polipeptid készítmények
|
|
TWI828269B
(zh)
|
2013-03-15 |
2024-01-01 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
|
DK2796145T3
(da)
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
|
EA201592022A1
(ru)
|
2013-06-28 |
2016-05-31 |
Байоджен Ма Инк. |
Расщепляемый тромбином линкер, содержащий xten, и его применение
|
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
|
WO2015023891A2
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Factor viii-xten fusions and uses thereof
|
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
|
EP4332839A3
(en)
|
2013-12-06 |
2024-06-05 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
SG10201913697UA
(en)
|
2014-01-10 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
WO2015107222A1
(en)
*
|
2014-01-20 |
2015-07-23 |
Octapharma Ag |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
|
JP6609561B2
(ja)
|
2014-02-04 |
2019-11-20 |
バイオジェン・エムエイ・インコーポレイテッド |
翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
RU2689338C2
(ru)
|
2014-08-04 |
2019-05-27 |
СиЭсЭл ЛИМИТЕД |
Состав фактора viii
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
CN107406493B
(zh)
|
2015-03-06 |
2021-08-13 |
康诺贝林伦瑙有限公司 |
具有改善的半衰期的经修饰的血管性血友病因子
|
|
CN107810194B
(zh)
|
2015-05-22 |
2021-10-08 |
康诺贝林伦瑙有限公司 |
用于制备经修饰的血管性血友病因子的方法
|
|
SG11201708755WA
(en)
|
2015-05-22 |
2017-12-28 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
CA2994547A1
(en)
|
2015-08-03 |
2017-02-09 |
Bioverativ Therapeutics Inc. |
Factor ix fusion proteins and methods of making and using same
|
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
|
US10189889B2
(en)
|
2015-11-13 |
2019-01-29 |
Baxalta Incorporated |
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
|
|
EA202190827A1
(ru)
|
2015-11-13 |
2021-11-30 |
Баксалта Инкорпорейтед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
|
|
US10806774B2
(en)
|
2016-01-07 |
2020-10-20 |
CSL Behring Lengnau AG |
Mutated truncated von Willebrand Factor
|
|
IL320404A
(en)
|
2016-02-01 |
2025-06-01 |
Bioverativ Therapeutics Inc |
Effective Factor VIII genes
|
|
KR102219859B1
(ko)
|
2016-06-24 |
2021-02-25 |
재단법인 목암생명과학연구소 |
재조합 단쇄 fviii 및 그 화학 접합물
|
|
US11046749B2
(en)
|
2016-06-24 |
2021-06-29 |
Mogam Institute For Biomedical Research |
Chimera protein comprising FVIII and vWF factors, and use thereof
|
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第ｖｉｉｉ因子とその誘導体の製造及び精製方法
|
|
CA3043397A1
(en)
|
2016-11-11 |
2018-05-17 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
EP3538133B1
(en)
|
2016-11-11 |
2021-02-17 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
US12257288B2
(en)
|
2016-12-02 |
2025-03-25 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
JP2020530436A
(ja)
|
2017-06-22 |
2020-10-22 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
トランケート型ｖｗｆによるｆｖｉｉｉの免疫原性の調節
|
|
CN120905307A
(zh)
|
2017-08-09 |
2025-11-07 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用途
|
|
CA3078625C
(en)
|
2017-10-09 |
2023-01-17 |
Terumo Bct Biotechnologies, Llc |
Lyophilization container and method of using same
|
|
US20210038744A1
(en)
|
2018-02-01 |
2021-02-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
|
KR20210005608A
(ko)
|
2018-04-04 |
2021-01-14 |
시질론 테라퓨틱스, 인크. |
이식 가능한 입자 및 관련 방법
|
|
CN112512555A
(zh)
|
2018-05-18 |
2021-03-16 |
比奥维拉迪维治疗股份有限公司 |
治疗血友病a的方法
|
|
WO2020018419A1
(en)
|
2018-07-16 |
2020-01-23 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
WO2020033863A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
WO2020061281A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
EP3923992A1
(en)
*
|
2019-02-15 |
2021-12-22 |
CRISPR Therapeutics AG |
Gene editing for hemophilia a with improved factor viii expression
|
|
CN113597532B
(zh)
|
2019-03-14 |
2023-02-17 |
泰尔茂比司特生物技术有限公司 |
冻干容器填充固定装置、系统及使用方法
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
MX2021009814A
(es)
*
|
2019-06-05 |
2022-10-27 |
Crispr Therapeutics Ag |
Edición de genes para hemofilia a con expresión mejorada del factor viii.
|
|
BR112021025426A2
(pt)
|
2019-06-19 |
2022-06-21 |
Bioverativ Therapeutics Inc |
Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
|
|
KR20220029733A
(ko)
|
2019-07-04 |
2022-03-08 |
체에스엘 베링 렝나우 아게 |
응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
|
|
JP2022549932A
(ja)
|
2019-09-30 |
2022-11-29 |
バイオベラティブ セラピューティクス インコーポレイテッド |
レンチウイルスベクター製剤
|
|
JP7680442B2
(ja)
|
2019-11-11 |
2025-05-20 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
|
|
CN114981299A
(zh)
|
2019-12-12 |
2022-08-30 |
武田药品工业株式会社 |
使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
|
|
JP7681268B2
(ja)
*
|
2020-03-30 |
2025-05-22 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
|
TW202208619A
(zh)
|
2020-06-24 |
2022-03-01 |
美商百歐維拉提夫治療公司 |
用於純化病毒載體之方法
|
|
JP2024527252A
(ja)
|
2021-06-14 |
2024-07-24 |
武田薬品工業株式会社 |
発現の増加した組み換えｆｖｉｉｉバリアントをコードするウイルスベクターを用いた、血友病ａの遺伝子療法
|
|
KR20240049332A
(ko)
|
2021-08-23 |
2024-04-16 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 인자 viii 유전자
|
|
JP2024537797A
(ja)
|
2021-09-30 |
2024-10-16 |
バイオベラティブ セラピューティクス インコーポレイテッド |
低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸
|
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|